Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 10/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015342 | 0.93 | CALCA (0.47) | CALCACYP2C9KCNH2LIPGKCNK3 | |
| SCHEMBL3842589 | 0.89 | CALCA (0.39) | CALCACYP2C9KCNH2LIPG | |
| SCHEMBL5016721 | 0.85 | CALCA (0.39) | CALCACYP2C9KCNH2LIPG | |
| SCHEMBL5013855 | 0.85 | CYP2C9 (0.41) | CALCACYP2C9KCNH2LIPGKCNK3 | |
| SCHEMBL13917222 | 0.85 | CYP2C9 (0.41) | CALCACYP2C9KCNH2KCNK3KCNE1 | |
| SCHEMBL5013896 | 0.84 | EGLN1 (0.38) | CYP2C9KCNH2RIPK1KCNK3 | |
| SCHEMBL13917387 | 0.84 | CYP2C9 (0.38) | CALCACYP2C9KCNH2KCNK3KCNE1 | |
| SCHEMBL13917436 | 0.84 | CYP2C9 (0.40) | CALCACYP2C9KCNH2LIPGRIPK1 | |
| SCHEMBL13917366 | 0.84 | CYP2C9 (0.41) | CYP2C9KCNH2KCNK3 | |
| SCHEMBL5011962 | 0.84 | CYP2C9 (0.38) | CALCACYP2C9KCNH2KCNK3KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | claimed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | CALCA 2267/4885CYP2C9 301/4885KCNH2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.